Fig. 1From: MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostatMYC-drives platinum resistant small cell lung cancer in vitro. A Cell lines derived from the Rb1−/−:Trp53−/− mouse model of small cell lung cancer were continuously cultured in an LD50 dose of carboplatin and platinum sensitivity of both platinum naïve and resistant closes determined following treatment with the indicated doses of carboplatin for 7 days. Data is the mean ± SD in three independent experiments. B MYC expression in naïve and platinum resistant mouse SCLC cell lines was determined by western blot. Data is representative of 3 independent experiments. C Rb1−/−:Trp53−/− mouse SCLC cell lines were stably transduced with empty vector (EV) or MYC encoding retrovirus (MYC) and MYC expression confirmed by western blot. Data is representative of 3 independent experiments. D The impact of stable MYC overexpression on platinum sensitivity was determined following 7 days exposure to the indicated doses of carboplatin. Data is the mean ± SD in three independent experimentsBack to article page